Use of Antifreeze Protein from Tenebrio molitor (TmAFP) in Vitrification of In Vitro-Produced Bovine Embryos: An Ultrastructural Study.

The objective of this study was to evaluate the effects of different concentrations of antifreeze protein (AFP) extracted from the larva of the beetle, Tenebrio molitor (TmAFP), on vitrification of in vitro-produced bovine embryos. In vitro-produced blastocysts were divided into three experimental groups and vitrified using a cryotop. TmAFP was added to the equilibrium solution (ES) and vitrification solution (VS) at a concentration of 0 ng/mL (control), 500 ng/mL (500TmAFP), or 1000 ng/mL (1000TmAFP). Vitrification was carried out by first placing the blastocysts in ES for 2 minutes (7.5% ethylene glycol [EG] and 7.5% dimethyl sulfoxide [DMSO]). The blastocysts were then transferred to VS (15% EG and 15% DMSO) and promptly deposited on a cryotop stem and submerged in liquid nitrogen. Warming was carried out in three steps with decreasing sucrose concentrations. After warming, the blast cells were cultured for 24 hours for subsequent survival analysis and ultrastructural evaluation. There was a significant difference in the survival rate and expansion in the 500TmAFP group compared with the other groups. The ultrastructural analysis revealed intracellular lesions in all vitrified embryos; however, the embryos of the 500TmAFP and 1000TmAFP groups showed fewer cytoplasmic lesions compared with the control group. Taken together, addition of TmAFP can mitigate cellular changes that involve organelles and cellular components essential for proper functioning and improve the viability of warmed and vitrified in vitro-produced bovine embryos.

Bioreactor Production Process of Spodoptera frugiperda multiple nucleopolyhedrovirus Biopesticide.

Spodoptera frugiperda (fall armyworm) is one of the most important maize pests in the world and the baculovirus Spodoptera frugiperda multiple nucleopolyhedrovirus (SfMNPV), a natural pathogen of this pest, has been used as a biopesticide for its control. At present, in vivo strategies at the commercial scale are employed by multiplying the virus in the host insect in biofactory facilities; however, in vitro large-scale production is an interesting alternative to overcome the limitations of baculoviruses massal production. This study aimed to develop the process of the SfMNPV in vitro production by evaluating the effects of different multiplicities of infection (MOI) and nutritional supplements, morphological and molecular analysis of the infection on the growth of Sf9 cells and virus production. The Bioreactor Stirred Tank Reactor (STR) approach with glutamine-supplemented Sf-900 III serum free culture medium, combined with the MOI of 1.0, showed the best viral production performance, with a specific productivity above 300 occlusion bodies (OBs)/cell and volumetric productivity of 9.0 × 1011 OBs/L.

Unraveling the Consequences of Oxygen Imbalance on Early Embryo Development: Exploring Mitigation Strategies.

Although well-established and adopted by commercial laboratories, the in vitro embryo production system still requires refinements to achieve its highest efficiency. Early embryonic development is a dynamic event, demanding suitable conditions to provide a high number of embryos with quality and competence. The first step to obtaining an optimized in vitro environment is to know the embryonic metabolism and energy request throughout the different stages of development. Oxygen plays a crucial role in several key biological processes necessary to sustain and complete embryonic development. Nonetheless, there is still controversy regarding the optimal in vitro atmospheric concentrations during culture. Herein, we discuss the impact of oxygen tension on the viability of in vitro-produced embryos during early development. The importance of oxygen tension is addressed as its roles regarding essential embryonic traits, including embryo production rates, embryonic cell viability, gene expression profile, epigenetic regulation, and post-cryopreservation survival. Finally, we highlight the damage caused by in vitro unbalanced oxygen tensions and strategies to mitigate the harmful effects.

In-vitro production and pre-validation of lyophilized canine platelet-rich plasma for therapeutic use / Produção e validação de plasma rico em plaquetas canino liofilizado para fins de utilização terapêutica

Platelet-rich plasma (PRP) has been considered a promising therapeutic alternative, since platelets are rich in growth factors that are used in the Regenerative Medicine field. However, fresh PRP cannot be stored for long periods. This study aimed to develop a protocol for obtaining lyophilized canine PRP capable of maintaining viability after its reconstitution. For that purpose, canine PRP extraction and lyophilization protocols were initially tested. Subsequently, assays were carried out to quantify the growth factors VEGF and TGF-β, before and after the lyophilization process, gelation test and the three-dimensional gel structure analysis of the reconstituted lyophilized PRP by electron microscopy, as well as in vitro cell proliferation test in lyophilized PRP gel. Additionally, the immunogenicity test was performed, using allogeneic samples of lyophilized PRP. The results showed that the lyophilized PRP had adequate therapeutic concentrations of growth factors VEGF and TGF-β (9.1pg/mL and 6161.6pg/mL, respectively). The reconstituted PRP gel after lyophilization showed an in vitro durability of 10 days. Its electron microscopy structure was similar to that of fresh PRP. In the cell proliferation test, an intense division process was verified in mesenchymal stem cells (MSCs) through the three-dimensional mesh structure of the lyophilized PRP gel. The immunogenicity test showed no evidence of an immune reaction. The findings were promising, suggesting the possibility of having a lyophilized canine PRP that can be marketed. New in vivo and in vitro studies must be carried out for therapeutic confirmation.(AU)

O plasma rico em plaquetas (PRP) é uma alternativa terapêutica promissora, pois as plaquetas são ricas em fatores de crescimento com ação na regeneração de tecidos. No entanto, o PRP fresco não pode ser armazenado por longos períodos. Esse trabalho teve como objetivo desenvolver um protocolo de obtenção de PRP liofilizado canino capaz de manter a viabilidade pós reconstituição. Portanto, foram testados diversos protocolos de extração e liofilização. Para validação do PRP canino liofilizado foi analisada a concentração dos fatores de crescimento VEGF e TGF-β antes e após o processo de liofilização, a estrutura tridimensional do PRP liofilizado reconstituído em forma de gel por microscopia eletrônica e seu efeito in vitro na proliferação de células-tronco mesenquimais. Os resultados demonstraram que o PRP liofilizado apresentou concentrações terapêuticas adequadas dos fatores de crescimento VEGF e TGF- β (9,1pg/ml e 6161,6pg/ml, respectivamente). O gel de PRP reconstituído após liofilização apresentou uma durabilidade in vitro de 10 dias, sua estrutura tridimensional mostrou-se semelhante ao PRP fresco e proporcionou intensa proliferação de células-tronco mesenquimais durante o cultivo. O teste de imunogenicidade não demonstrou evidências de reação imune. Os achados foram promissores, sugerindo a possibilidade de uso de PRP canino liofilizado para o mercado. Novos estudos in vivo e in vitro deverão ser conduzidos para comprovação terapêutica.(AU)

In-vitro production and pre-validation of lyophilized canine platelet-rich plasma for therapeutic use

ABSTRACT: Platelet-rich plasma (PRP) has been considered a promising therapeutic alternative, since platelets are rich in growth factors that are used in the Regenerative Medicine field. However, fresh PRP cannot be stored for long periods. This study aimed to develop a protocol for obtaining lyophilized canine PRP capable of maintaining viability after its reconstitution. For that purpose, canine PRP extraction and lyophilization protocols were initially tested. Subsequently, assays were carried out to quantify the growth factors VEGF and TGF-, before and after the lyophilization process, gelation test and the three-dimensional gel structure analysis of the reconstituted lyophilized PRP by electron microscopy, as well as in vitro cell proliferation test in lyophilized PRP gel. Additionally, the immunogenicity test was performed, using allogeneic samples of lyophilized PRP. The results showed that the lyophilized PRP had adequate therapeutic concentrations of growth factors VEGF and TGF- (9.1pg/mL and 6161.6pg/mL, respectively). The reconstituted PRP gel after lyophilization showed an in vitro durability of 10 days. Its electron microscopy structure was similar to that of fresh PRP. In the cell proliferation test, an intense division process was verified in mesenchymal stem cells (MSCs) through the three-dimensional mesh structure of the lyophilized PRP gel. The immunogenicity test showed no evidence of an immune reaction. The findings were promising, suggesting the possibility of having a lyophilized canine PRP that can be marketed. New in vivo and in vitro studies must be carried out for therapeutic confirmation.

RESUMO: O plasma rico em plaquetas (PRP) é uma alternativa terapêutica promissora, pois as plaquetas são ricas em fatores de crescimento com ação na regeneração de tecidos. No entanto, o PRP fresco não pode ser armazenado por longos períodos. Esse trabalho teve como objetivo desenvolver um protocolo de obtenção de PRP liofilizado canino capaz de manter a viabilidade pós reconstituição. Portanto, foram testados diversos protocolos de extração e liofilização. Para validação do PRP canino liofilizado foi analisada a concentração dos fatores de crescimento VEGF e TGF- antes e após o processo de liofilização, a estrutura tridimensional do PRP liofilizado reconstituído em forma de gel por microscopia eletrônica e seu efeito in vitro na proliferação de células-tronco mesenquimais. Os resultados demonstraram que o PRP liofilizado apresentou concentrações terapêuticas adequadas dos fatores de crescimento VEGF e TGF- (9,1pg/ml e 6161,6pg/ml, respectivamente). O gel de PRP reconstituído após liofilização apresentou uma durabilidade in vitro de 10 dias, sua estrutura tridimensional mostrou-se semelhante ao PRP fresco e proporcionou intensa proliferação de células-tronco mesenquimais durante o cultivo. O teste de imunogenicidade não demonstrou evidências de reação imune. Os achados foram promissores, sugerindo a possibilidade de uso de PRP canino liofilizado para o mercado. Novos estudos in vivo e in vitro deverão ser conduzidos para comprovação terapêutica.

In-vitro production and pre-validation of lyophilized canine platelet-rich plasma for therapeutic use / Produção e validação de plasma rico em plaquetas canino liofilizado para fins de utilização terapêutica

Platelet-rich plasma (PRP) has been considered a promising therapeutic alternative, since platelets are rich in growth factors that are used in the Regenerative Medicine field. However, fresh PRP cannot be stored for long periods. This study aimed to develop a protocol for obtaining lyophilized canine PRP capable of maintaining viability after its reconstitution. For that purpose, canine PRP extraction and lyophilization protocols were initially tested. Subsequently, assays were carried out to quantify the growth factors VEGF and TGF-β, before and after the lyophilization process, gelation test and the three-dimensional gel structure analysis of the reconstituted lyophilized PRP by electron microscopy, as well as in vitro cell proliferation test in lyophilized PRP gel. Additionally, the immunogenicity test was performed, using allogeneic samples of lyophilized PRP. The results showed that the lyophilized PRP had adequate therapeutic concentrations of growth factors VEGF and TGF-β (9.1pg/mL and 6161.6pg/mL, respectively). The reconstituted PRP gel after lyophilization showed an in vitro durability of 10 days. Its electron microscopy structure was similar to that of fresh PRP. In the cell proliferation test, an intense division process was verified in mesenchymal stem cells (MSCs) through the three-dimensional mesh structure of the lyophilized PRP gel. The immunogenicity test showed no evidence of an immune reaction. The findings were promising, suggesting the possibility of having a lyophilized canine PRP that can be marketed. New in vivo and in vitro studies must be carried out for therapeutic confirmation.(AU)

O plasma rico em plaquetas (PRP) é uma alternativa terapêutica promissora, pois as plaquetas são ricas em fatores de crescimento com ação na regeneração de tecidos. No entanto, o PRP fresco não pode ser armazenado por longos períodos. Esse trabalho teve como objetivo desenvolver um protocolo de obtenção de PRP liofilizado canino capaz de manter a viabilidade pós reconstituição. Portanto, foram testados diversos protocolos de extração e liofilização. Para validação do PRP canino liofilizado foi analisada a concentração dos fatores de crescimento VEGF e TGF-β antes e após o processo de liofilização, a estrutura tridimensional do PRP liofilizado reconstituído em forma de gel por microscopia eletrônica e seu efeito in vitro na proliferação de células-tronco mesenquimais. Os resultados demonstraram que o PRP liofilizado apresentou concentrações terapêuticas adequadas dos fatores de crescimento VEGF e TGF- β (9,1pg/ml e 6161,6pg/ml, respectivamente). O gel de PRP reconstituído após liofilização apresentou uma durabilidade in vitro de 10 dias, sua estrutura tridimensional mostrou-se semelhante ao PRP fresco e proporcionou intensa proliferação de células-tronco mesenquimais durante o cultivo. O teste de imunogenicidade não demonstrou evidências de reação imune. Os achados foram promissores, sugerindo a possibilidade de uso de PRP canino liofilizado para o mercado. Novos estudos in vivo e in vitro deverão ser conduzidos para comprovação terapêutica.(AU)

How can we improve embryo production and pregnancy outcomes of Holstein embryos produced in vitro? (12 years of practical results at a California dairy farm).

Genomic evaluations have revolutionized dairy cattle breeding, and the demand for embryos produced from very young heifers with high genetic merit has increased over time. The combination of low oocyte recovery, young age of donors, and milk production status can make the in vitro embryo production (IVP) of Holstein cattle incredibly challenging. Several factors need to be coordinated to obtain a live calf from an IVP embryo, but the quality of the oocyte at the start of the process is one of the key factors. Aspects related to oocyte quality, laboratory quality control, embryo quality and recipient selection are addressed here, based on the measures that the RuAnn Genetics Laboratory (Riverdale, California, USA) adopted in the last 12 years, with the goal of improving production of live, healthy calves from Holstein embryos. Follicular wave synchronization and stimulation with follicular stimulating hormone (FSH) is necessary to improve oocyte quality and consequently embryo production. Laboratory quality control and the use of high-quality supplies are essential to reduce variability in production and facilitate identification of other factors that might interfere with embryo production. High pregnancy rates can be achieved with good quality embryos selected at optimal time and stage of development, transferred by an experienced embryo transfer (ET) technician, to well managed recipients 7 or 8 days after estrus. Attention to detail at every step of the process is crucial to success.

Influência da progesterona injetável na taxa de prenhez de novilhas receptoras de embriões bovinos / Influence of injectable progesterone on the pregnancy rate of heifers receiving bovine embryos

Background: In vitro embryo production (IVEP) allows the spread of superior animal genetics, but pregnancy rates show a high variability with this biotechnique. In the initial stage of pregnancy, progesterone plays a fundamental role in uterine preparation, acting on embryonic growth, implantation, and development. However, on the day of the IVEP transfer to the recipients, progesterone levels may be lower than that expected, influencing the uterine environment and, consequently, the pregnancy rate. Therefore, the objective of this study was to evaluate the pregnancy rate in heifers after the administration of injectable progesterone (P4) in the fixed-time embryo transfer (FTET) protocol. Materials, Methods & Results: The experiment was conducted inside a rural property near the city of Rio Branco, Acre, Brazil. The experimental group consisted of 232 animals, including 78 zebuine (Bos indicus) and 154 mixed (½ blood B. indicus and ½ blood B. taurus) animals, aged between 16 and 24 months, with a mean weight of 300 and 330 kg for zebuine and mixed animals, respectively. The selected animals were previously synchronized using the progesteroneestrogen-prostaglandin-estrogen protocol. Embryo transfer was performed on day 18 of the protocol, which was 9 days after the removal of intravaginal progesterone implant. On day 15 of the protocol, that is, 144 h (6 days) after the device removal, the animals were randomly distributed into two experimental groups: Control Group (CG; 0.5 mL of 0.9% saline solution, intramuscular) and Treated Group (P4G; 0.5 mL of injectable P4, 150 mg, intramuscular). Chi-square test was used for the statistical analysis of the pregnancy rate at a 5% probability. After 23 days of embryo transfer, pregnancy was diagnosed by ultrasonography. The general pregnancy rate, considering all groups (CG and P4G) and breeds included, was 55.17% (128/232). The pregnancy rates of the P4G and CG groups, regardless of breeds, were...

How can we improve embryo production and pregnancy outcomes of Holstein embryos produced in vitro? (12 years of practical results at a California dairy farm)

Genomic evaluations have revolutionized dairy cattle breeding, and the demand for embryos produced from very young heifers with high genetic merit has increased over time. The combination of low oocyte recovery, young age of donors, and milk production status can make the in vitro embryo production (IVP) of Holstein cattle incredibly challenging. Several factors need to be coordinated to obtain a live calf from an IVP embryo, but the quality of the oocyte at the start of the process is one of the key factors. Aspects related to oocyte quality, laboratory quality control, embryo quality and recipient selection are addressed here, based on the measures that the RuAnn Genetics Laboratory (Riverdale, California, USA) adopted in the last 12 years, with the goal of improving production of live, healthy calves from Holstein embryos. Follicular wave synchronization and stimulation with follicular stimulating hormone (FSH) is necessary to improve oocyte quality and consequently embryo production. Laboratory quality control and the use of high-quality supplies are essential to reduce variability in production and facilitate identification of other factors that might interfere with embryo production. High pregnancy rates can be achieved with good quality embryos selected at optimal time and stage of development, transferred by an experienced embryo transfer (ET) technician, to well managed recipients 7 or 8 days after estrus. Attention to detail at every step of the process is crucial to success.

Substituição parcial do soro fetal bovino durante cultivo in vitro reduz a concentração de fosfolipídios em embriões bovinos produzidos in vitro / Partial replacement of fetal bovine serum during in vitro culture decreases phospholipid content in in vitro produced bovine embryos

Soro fetal bovino (SFB) e albumina sérica bovina (BSA) são componentes importantes do cultivo in vitro (CIV) de embriões bovinos, porém são frequentemente associados ao acúmulo excessivo de lipídios, podendo prejudicar o desenvolvimento embrionário. Este estudo teve como objetivo substituir parcialmente o SFB por BSA V FAF durante o CIV de embriões bovinos, avaliar a produção embrionária e quantificar os lipídios dos embriões, SFB e dos meios de cultivo. Para isto, os embriões desenvolveram em meios de cultivo suplementados com 10% de SFB (SFB10%) ou 5% de SFB e 0.03g de BSA V FAF (SFB5%/BSA). O conteúdo lipídico foi avaliado por UHPLC-MS/MS. A análise estatística foi feita utilizando teste t e ANOVA. A substituição parcial de SFB por BSA V FAF não alterou a produção embrionária. Nos dois grupos foram identificados 10 fosfolipídios e três deles, DOPC (p=0,037), POPG (p=0,046) e C24: 1-SM (p=0,009), apresentaram menores concentrações no meio SFB5%/BSA. Os fosfolipídios identificados nos embriões coincidem com os encontrados no SFB e meios de cultivo e quatro deles DOPC (p=0,013), DPPC (p=0,004), POPG (p=0,05) e C24:1-SM (p=0,003) diminuíram a concentração com a redução do SFB. A substituição parcial do SFB diminui a concentração de fosfolipídios sem prejudicar a produção embrionária, sugerindo uma melhora nas técnicas relacionadas ao cultivo in vitro.(AU)

Fetal bovine serum (FBS) and bovine serum albumin (BSA) are important components during bovine embryo in vitro culture (IVC), but they are associated with excess of embryonic lipid, which might impair embryo development. This study aimed to partially replace FBS by BSA V FAF during bovine IVC, evaluate embryo production and quantify the phospholipid content in produced embryos, SFB and IVC medium. The embryos were in vitro cultured in medium supplied with 10% of FBS (FBS10%) or with 5% of FBS plus 0.03 g BSA V FAF (FBS5%/BSA). The lipid content was evaluated using UHPLC-MS/MS and statistical analysis was performed using t-test and ANOVA. The partial replacement of FBS by BSA V FAF did not alter embryo production. Ten phospholipids were identified in both groups and three of them, DOPC (p=0.037), POPG (p=0.046) and C24: 1-SM (p=0.009) presented lower concentration in FBS5%/BSA culture medium. The phospholipids identified on embryos matches with those found on SFB and culture medium and four of them DOPC (p=0.013), DPPC (p=0.004), POPG (p=0.05) and C24:1- SM (p=0.003) reduced its concentration when FBS was reduced. Theses founds shown that the FBS partial replacement reduces phospholipids content in embryos but do not decrease embryo production, suggesting a technical improvement.(AU)

How can we improve embryo production and pregnancy outcomes of Holstein embryos produced in vitro? (12 years of practical results at a California dairy farm)

Genomic evaluations have revolutionized dairy cattle breeding, and the demand for embryos produced from very young heifers with high genetic merit has increased over time. The combination of low oocyte recovery, young age of donors, and milk production status can make the in vitro embryo production (IVP) of Holstein cattle incredibly challenging. Several factors need to be coordinated to obtain a live calf from an IVP embryo, but the quality of the oocyte at the start of the process is one of the key factors. Aspects related to oocyte quality, laboratory quality control, embryo quality and recipient selection are addressed here, based on the measures that the RuAnn Genetics Laboratory (Riverdale, California, USA) adopted in the last 12 years, with the goal of improving production of live, healthy calves from Holstein embryos. Follicular wave synchronization and stimulation with follicular stimulating hormone (FSH) is necessary to improve oocyte quality and consequently embryo production. Laboratory quality control and the use of high-quality supplies are essential to reduce variability in production and facilitate identification of other factors that might interfere with embryo production. High pregnancy rates can be achieved with good quality embryos selected at optimal time and stage of development, transferred by an experienced embryo transfer (ET) technician, to well managed recipients 7 or 8 days after estrus. Attention to detail at every step of the process is crucial to success.(AU)

Substituição parcial do soro fetal bovino durante cultivo in vitro reduz a concentração de fosfolipídios em embriões bovinos produzidos in vitro / Partial replacement of fetal bovine serum during in vitro culture decreases phospholipid content in in vitro produced bovine embryos

Soro fetal bovino (SFB) e albumina sérica bovina (BSA) são componentes importantes do cultivo in vitro (CIV) de embriões bovinos, porém são frequentemente associados ao acúmulo excessivo de lipídios, podendo prejudicar o desenvolvimento embrionário. Este estudo teve como objetivo substituir parcialmente o SFB por BSA V FAF durante o CIV de embriões bovinos, avaliar a produção embrionária e quantificar os lipídios dos embriões, SFB e dos meios de cultivo. Para isto, os embriões desenvolveram em meios de cultivo suplementados com 10% de SFB (SFB10%) ou 5% de SFB e 0.03g de BSA V FAF (SFB5%/BSA). O conteúdo lipídico foi avaliado por UHPLC-MS/MS. A análise estatística foi feita utilizando teste t e ANOVA. A substituição parcial de SFB por BSA V FAF não alterou a produção embrionária. Nos dois grupos foram identificados 10 fosfolipídios e três deles, DOPC (p=0,037), POPG (p=0,046) e C24: 1-SM (p=0,009), apresentaram menores concentrações no meio SFB5%/BSA. Os fosfolipídios identificados nos embriões coincidem com os encontrados no SFB e meios de cultivo e quatro deles DOPC (p=0,013), DPPC (p=0,004), POPG (p=0,05) e C24:1-SM (p=0,003) diminuíram a concentração com a redução do SFB. A substituição parcial do SFB diminui a concentração de fosfolipídios sem prejudicar a produção embrionária, sugerindo uma melhora nas técnicas relacionadas ao cultivo in vitro.

Fetal bovine serum (FBS) and bovine serum albumin (BSA) are important components during bovine embryo in vitro culture (IVC), but they are associated with excess of embryonic lipid, which might impair embryo development. This study aimed to partially replace FBS by BSA V FAF during bovine IVC, evaluate embryo production and quantify the phospholipid content in produced embryos, SFB and IVC medium. The embryos were in vitro cultured in medium supplied with 10% of FBS (FBS10%) or with 5% of FBS plus 0.03 g BSA V FAF (FBS5%/BSA). The lipid content was evaluated using UHPLC-MS/MS and statistical analysis was performed using t-test and ANOVA. The partial replacement of FBS by BSA V FAF did not alter embryo production. Ten phospholipids were identified in both groups and three of them, DOPC (p=0.037), POPG (p=0.046) and C24: 1-SM (p=0.009) presented lower concentration in FBS5%/BSA culture medium. The phospholipids identified on embryos matches with those found on SFB and culture medium and four of them DOPC (p=0.013), DPPC (p=0.004), POPG (p=0.05) and C24:1- SM (p=0.003) reduced its concentration when FBS was reduced. Theses founds shown that the FBS partial replacement reduces phospholipids content in embryos but do not decrease embryo production, suggesting a technical improvement.

Embryo competence and cryosurvival: Molecular and cellular features.

Global cattle genetic market is experiencing a change of strategy, large genetic companies, traditionally recognized in the artificial insemination field, have also begun to operate in the embryo market. Consequently, the demand for in vitro produced (IVP) embryos has grown. However, the overall efficiency of the biotechnology process remains low. Additionally, the lack of homogeneity of post-cryopreservation survival results of IVP embryos still impairing a massive dissemination of this biotechnology in the field. A great challenge for in vitro production labs is to increase the amount of embryos produced with exceptional quality after each round of in vitro fertilization. Herein, we discuss the molecular and cellular features associated with the competence and cryosurvival of IVP embryos. First, morphofunctional, cellular and molecular competence of the embryos were addressed and a relationship between embryo developmental ability and quality were established with cryosurvival and pregnancy success. Additionally, determinant factors of embryo competence and cryosurvival were discussed including the following effects: genotype, oocyte quality and follicular microenvironment, in vitro production conditions, and lipids and other determining molecules. Finally, embryo cryopreservation aspects were addressed and an embryo-focused approach to improve cryosurvival was presented.

Embryo competence and cryosurvival: Molecular and cellular features

Global cattle genetic market is experiencing a change of strategy, large genetic companies, traditionally recognized in the artificial insemination field, have also begun to operate in the embryo market. Consequently, the demand for in vitro produced (IVP) embryos has grown. However, the overall efficiency of the biotechnology process remains low. Additionally, the lack of homogeneity of post-cryopreservation survival results of IVP embryos still impairing a massive dissemination of this biotechnology in the field. A great challenge for in vitro production labs is to increase the amount of embryos produced with exceptional quality after each round of in vitro fertilization. Herein, we discuss the molecular and cellular features associated with the competence and cryosurvival of IVP embryos. First, morphofunctional, cellular and molecular competence of the embryos were addressed and a relationship between embryo developmental ability and quality were established with cryosurvival and pregnancy success. Additionally, determinant factors of embryo competence and cryosurvival were discussed including the following effects: genotype, oocyte quality and follicular microenvironment, in vitro production conditions, and lipids and other determining molecules. Finally, embryo cryopreservation aspects were addressed and an embryofocused approach to improve cryosurvival was presented.(AU)

Embryo competence and cryosurvival: Molecular and cellular features

Global cattle genetic market is experiencing a change of strategy, large genetic companies, traditionally recognized in the artificial insemination field, have also begun to operate in the embryo market. Consequently, the demand for in vitro produced (IVP) embryos has grown. However, the overall efficiency of the biotechnology process remains low. Additionally, the lack of homogeneity of post-cryopreservation survival results of IVP embryos still impairing a massive dissemination of this biotechnology in the field. A great challenge for in vitro production labs is to increase the amount of embryos produced with exceptional quality after each round of in vitro fertilization. Herein, we discuss the molecular and cellular features associated with the competence and cryosurvival of IVP embryos. First, morphofunctional, cellular and molecular competence of the embryos were addressed and a relationship between embryo developmental ability and quality were established with cryosurvival and pregnancy success. Additionally, determinant factors of embryo competence and cryosurvival were discussed including the following effects: genotype, oocyte quality and follicular microenvironment, in vitro production conditions, and lipids and other determining molecules. Finally, embryo cryopreservation aspects were addressed and an embryofocused approach to improve cryosurvival was presented.

Use of a colloid to optimize centrifugation in the selection of bovine sperm for IVF / Uso de um coloide para otimizar a centrifugação na seleção de espermatozoides bovinos para FIV

This study aimed to evaluate the effect of the force and duration of centrifugation and the impact of cushioned centrifugation on sperm selection by Percoll gradient, on sperm quality and development kinetics of in vitro produced bovine embryos. Two experiments were performed. In Experiment I, a pool of semen was selected by Percoll gradients and the pellet was divided into four groups and distributed in a 2 × 2 factorial, with two forces (2200 × g or 9000 × g) and two durations (1 min or 3 min) of centrifugation. In Experiment II, semen was divided into two groups and selected by Percoll gradient with Cushion Fluid (CF) or without CF (Control) in the second centrifugation. The morphofunctionality, biochemical characteristics and fertilizing capacity of the selected sperms were evaluated. In addition, the development of the resulting bovine embryos was monitored for 48 h post-insemination. Duncan and Chi-square tests (P < 0.05) were used to compare the means. In Experiment I, there was a significant increase in sperm vigor (P < 0.05) after sperm selection in all treatments. The force and duration of centrifugation did not have any effect on sperm motility, vigor, and recovery rate among the different treatments (P > 0.05). In Experiment II, the recovery rate and reactive oxygen species (ROS) production in semen were similar among treatments (P > 0.05) although a higher ROS production was observed in the CF fertilization medium. Total fertilization rate was superior in the CF group (65.4 ± 5.3%) compared to that in Control (39.6 ± 4.9%). However, the normal fertilization and cleavage rate did not differ between the Control (94 ± 6.3% and 58.3 ± 8.3%) and CF (89 ± 7.1% and 75.0 ± 7.3%) groups. The reduction in the force and duration of centrifugation did not decrease the sperm recovery during selection by the Percoll gradient and the use of CF in the second centrifugation did not affect the normal fertilization and development of bovine IVF embryos up to 48 h.(AU)

Esse estudo objetivou avaliar o efeito da força e duração da centrifugação, e o impacto da centrifugação amortecida na seleção espermática por gradientes de Percoll, na qualidade espermática e cinética do desenvolvimento de embriões bovinos produzidos in vitro. Dois experimentos foram realizados. No experimento I, um pool de sêmen foi selecionado por gradientes de Percoll e o pellet dividido em quatro grupos e distribuído em um fatorial 2 x 2, com duas forças (2200 e 9000 X g) e dois tempos (1 e 3 min) de centrifugação. No Experimento II, o sêmen foi dividido em dois grupos e selecionado com (CF) ou sem CushionFluid (Controle) na segunda centrifugação. A morfofuncionalidade, características bioquímicas e capacidade fecundante dos espermatozoides selecionados foram avaliadas. Além disso, o desenvolvimento dos embriões bovinos resultantes foi monitorado por 48 horas pós-inseminação. Os testes Duncan e Qui-quadrado (P<0,05) foram usados para comparar as médias. No Experimento I, houve um aumento significativo no vigor após a seleção espermática para todos os tratamentos. A força e a duração da centrifugação não tiveram nenhum efeito na motilidade, vigor e recuperação espermática entre os diferentes tratamentos (P > 0.05). No Experimento II, a taxa de recuperação e a produção de espécies reativas de oxigênio (EROs) no sêmen foram similares entre os tratamentos (P>0,05), embora a maior produção de EROs foi observada no meio de fecundação do grupo CF. A taxa de fecundação total, foi superior no grupo CF (65.4±5.3%) comparada com o Controle (39.6±4.9%). Entretanto a fecundação normal e a taxa de clivagem não diferiram entre os grupos Controle (94±6.3% e 58.3±8.3%) e CF (89±7.1% and 75.0±7.3%). A redução na força e duração da centrifugação não diminuiu a recuperação espermática durante a seleção por gradientes de Percoll e o uso de CF na segunda centrifugação não influenciou a fecundação normal e o desenvolvimento de embriões bovinos PIV até 48 horas.(AU)

Temporal expression of pluripotency-associated transcription factors in sheep and cattle preimplantation embryos.

SummaryPluripotency-associated transcription factors (PATFs) modulate gene expression during early mammalian embryogenesis. Despite a strong understanding of PATFs during mouse embryogenesis, limited progress has been made in ruminants. This work aimed to describe the temporal expression of eight PATFs during both sheep and cattle preimplantation development. Transcript availability of PATFs was evaluated by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) in eggs, cleavage-stage embryos, morulae, and blastocysts. Transcripts of five genes were detected in all developmental stages of both species (KLF5, OCT4, RONIN, ZFP281, and ZFX). Furthermore, CMYC was detected in all cattle samples but was found from cleavage-stage onwards in sheep. In contrast, NR0B1 was detected in all sheep samples but was not detected in cattle morulae. GLIS1 displayed the most significant variation in temporal expression between species, as this PATF was only detected in cattle eggs and sheep cleavage-stage embryos and blastocysts. In silico analysis suggested that cattle and sheep PATFs share similar size, isometric point and molecular weight. A phenetic analysis showed two patterns of PATF clustering between cattle and sheep, among several mammalian species. In conclusion, the temporal expression of pluripotency-associated transcription factors differs between sheep and cattle, suggesting species-specific regulation during preimplantation development.

Use of a colloid to optimize centrifugation in the selection of bovine sperm for IVF / Uso de um coloide para otimizar a centrifugação na seleção de espermatozoides bovinos para FIV

This study aimed to evaluate the effect of the force and duration of centrifugation and the impact of cushioned centrifugation on sperm selection by Percoll gradient, on sperm quality and development kinetics of in vitro produced bovine embryos. Two experiments were performed. In Experiment I, a pool of semen was selected by Percoll gradients and the pellet was divided into four groups and distributed in a 2 × 2 factorial, with two forces (2200 × g or 9000 × g) and two durations (1 min or 3 min) of centrifugation. In Experiment II, semen was divided into two groups and selected by Percoll gradient with Cushion Fluid (CF) or without CF (Control) in the second centrifugation. The morphofunctionality, biochemical characteristics and fertilizing capacity of the selected sperms were evaluated. In addition, the development of the resulting bovine embryos was monitored for 48 h post-insemination. Duncan and Chi-square tests (P 0.05). In Experiment II, the recovery rate and reactive oxygen species (ROS) production in semen were similar among treatments (P > 0.05) although a higher ROS production was observed in the CF fertilization medium. Total fertilization rate was superior in the CF group (65.4 ± 5.3%) compared to that in Control (39.6 ± 4.9%). However, the normal fertilization and cleavage rate did not differ between the Control (94 ± 6.3% and 58.3 ± 8.3%) and CF (89 ± 7.1% and 75.0 ± 7.3%) groups. The reduction in the force and duration of centrifugation did not decrease the sperm recovery during selection by the Percoll gradient and the use of CF in the second centrifugation did not affect the normal fertilization and development of bovine IVF embryos up to 48 h.

Esse estudo objetivou avaliar o efeito da força e duração da centrifugação, e o impacto da centrifugação amortecida na seleção espermática por gradientes de Percoll, na qualidade espermática e cinética do desenvolvimento de embriões bovinos produzidos in vitro. Dois experimentos foram realizados. No experimento I, um pool de sêmen foi selecionado por gradientes de Percoll e o pellet dividido em quatro grupos e distribuído em um fatorial 2 x 2, com duas forças (2200 e 9000 X g) e dois tempos (1 e 3 min) de centrifugação. No Experimento II, o sêmen foi dividido em dois grupos e selecionado com (CF) ou sem CushionFluid (Controle) na segunda centrifugação. A morfofuncionalidade, características bioquímicas e capacidade fecundante dos espermatozoides selecionados foram avaliadas. Além disso, o desenvolvimento dos embriões bovinos resultantes foi monitorado por 48 horas pós-inseminação. Os testes Duncan e Qui-quadrado (P 0.05). No Experimento II, a taxa de recuperação e a produção de espécies reativas de oxigênio (EROs) no sêmen foram similares entre os tratamentos (P>0,05), embora a maior produção de EROs foi observada no meio de fecundação do grupo CF. A taxa de fecundação total, foi superior no grupo CF (65.4±5.3%) comparada com o Controle (39.6±4.9%). Entretanto a fecundação normal e a taxa de clivagem não diferiram entre os grupos Controle (94±6.3% e 58.3±8.3%) e CF (89±7.1% and 75.0±7.3%). A redução na força e duração da centrifugação não diminuiu a recuperação espermática durante a seleção por gradientes de Percoll e o uso de CF na segunda centrifugação não influenciou a fecundação normal e o desenvolvimento de embriões bovinos PIV até 48 horas.

Influence of commercially available follicle stimulating hormone on the in vitro maturation of bovine oocytes / Influência do hormônio folículo-estimulante disponível comercialmente sobre a maturação in vitro de oócitos bovinos

The work aimed (Experiment I) to compare commercial representations of porcine follicle stimulating hormone (FSH, Pluset® vs. Folltropin®) in concentration (10 μg/mL) and time (24 h) standard (more used in protocols of in vitro maturation, IVM); (Experiment II) to evaluate the best incubation time (6 h vs. 16 h vs. 24 h) and, (Experiment III) to analyze varying concentrations (1.0 μg/mL vs. 2.5 μg/mL vs. 10.0 μg/mL) of representations of FSH on the IVM of bovine oocytes. Thus, oocytes were recovered and submitted to IVM under appropriate conditions. After the IVM, oocytes were evaluated for expansion of cumulus cells (CCs), presence of the first polar body (1PB) and metaphase plate (MII). All the data were analyzed by the Fisher exact test (P < 0.05). Initially, in Experiment I, no difference (P > 0.05) was observed in maturation rates of the oocytes incubated with FSH Pluset® or Folltropin®, assessed by expansion of CCs (97.6% vs. 94.3%), presence of 1PB (76.6% vs. 69.4%) and MII (70.0% vs. 68.6%). In Experiment II, when the incubation time with FSH was evaluated, both Pluset® as Folltropin® showed lower rate of expansion of CCs when they were present only in the first 6 h of IVM. As for presence of 1PB, differences were observed in relation to Pluset® while Folltropin® showed similar results in all incubation times. Regarding the MII, no difference was observed between the incubation times with FSH Pluset® and Folltropin®. In Experiment III, no difference was observed in the expansion of CCs, presence of 1PB and MII for concentrations evaluated FSH Pluset® and Folltropin®. Therefore, the FSH Pluset® and Folltropin® have the same efficiency in IVM of bovine oocytes. Regarding the incubation time, it is recommended to maintain FSH (Pluset® or Folltropin®) throughout the period of IVM, since there was no difference in the results of presence of MII...(AU)

O trabalho objetivou (Experimento I) comparar representações comerciais do hormônio folículo estimulante suíno (FSH, Pluset® vs. Folltropin®) na concentração (10 μg/mL) e tempo (24 h) padrão (mais utilizados nos protocolos de maturação in vitro, MIV); (Experimento II) avaliar o melhor tempo de incubação (6 h vs. 16 h vs. 24 h) e, (Experimento III) analisar concentrações variáveis (1,0 μg/mL vs. 2,5 μg/mL vs. 10,0 μg/mL) das representações de FSH sobre a MIV de oócitos bovinos. Para tanto, oócitos foram recuperados e submetidos a MIV em condições adequadas. Após a MIV, oócitos foram avaliados quanto à expansão das células do cumulus (CCs), presença do primeiro corpúsculo polar (1CP) e placa metafásica (MII). Todos os dados foram analisados pelo teste exato de Fisher (P < 0,05). Inicialmente, no Experimento I, nenhuma diferença foi observada (P > 0,05) nas taxas de maturação de oócitos incubados com FSH Pluset® ou Folltropin®, avaliadas pela expansão das CCs (97,6% vs. 94,3%), presença de 1CP (76,6% vs. 69,4%) e MII (70,0% vs. 68,6%). No Experimento II, quanto ao tempo de incubação com FSH foi avaliado, tanto Pluset® quanto Folltropin® mostraram uma menor taxa de expansão de CCs somente nas primeiras 6 h de MIV. Quanto à presença de 1CP, diferenças foram observadas em relação ao Pluset® enquanto o Folltropin® mostrou resultados similares em todos os tempos de incubação. Em relação à MII, nenhuma diferença foi observada entre os tempos de incubação com o FSH Pluset® e Folltropin®. No Experimento III, nenhuma diferença foi observada na expansão das CCs, presença do 1CP e MII para as concentrações avaliadas de FSH Pluset® e Folltropin®. Portanto, FSH Pluset® e Folltropin® tem a mesma eficiência na MIV de oócitos bovinos. Em relação ao tempo de incubação, é recomendado manter o FSH (Pluset® or Folltropin®) ao longo do período da MIV, uma vez que nenhuma diferença foi observada nos resultados da presença de MII...(AU)

Influence of commercially available follicle stimulating hormone on the in vitro maturation of bovine oocytes / Influência do hormônio folículo-estimulante disponível comercialmente sobre a maturação in vitro de oócitos bovinos

The work aimed (Experiment I) to compare commercial representations of porcine follicle stimulating hormone (FSH, Pluset® vs. Folltropin®) in concentration (10 μg/mL) and time (24 h) standard (more used in protocols of in vitro maturation, IVM); (Experiment II) to evaluate the best incubation time (6 h vs. 16 h vs. 24 h) and, (Experiment III) to analyze varying concentrations (1.0 μg/mL vs. 2.5 μg/mL vs. 10.0 μg/mL) of representations of FSH on the IVM of bovine oocytes. Thus, oocytes were recovered and submitted to IVM under appropriate conditions. After the IVM, oocytes were evaluated for expansion of cumulus cells (CCs), presence of the first polar body (1PB) and metaphase plate (MII). All the data were analyzed by the Fisher exact test (P 0.05) was observed in maturation rates of the oocytes incubated with FSH Pluset® or Folltropin®, assessed by expansion of CCs (97.6% vs. 94.3%), presence of 1PB (76.6% vs. 69.4%) and MII (70.0% vs. 68.6%). In Experiment II, when the incubation time with FSH was evaluated, both Pluset® as Folltropin® showed lower rate of expansion of CCs when they were present only in the first 6 h of IVM. As for presence of 1PB, differences were observed in relation to Pluset® while Folltropin® showed similar results in all incubation times. Regarding the MII, no difference was observed between the incubation times with FSH Pluset® and Folltropin®. In Experiment III, no difference was observed in the expansion of CCs, presence of 1PB and MII for concentrations evaluated FSH Pluset® and Folltropin®. Therefore, the FSH Pluset® and Folltropin® have the same efficiency in IVM of bovine oocytes. Regarding the incubation time, it is recommended to maintain FSH (Pluset® or Folltropin®) throughout the period of IVM, since there was no difference in the results of presence of MII...

O trabalho objetivou (Experimento I) comparar representações comerciais do hormônio folículo estimulante suíno (FSH, Pluset® vs. Folltropin®) na concentração (10 μg/mL) e tempo (24 h) padrão (mais utilizados nos protocolos de maturação in vitro, MIV); (Experimento II) avaliar o melhor tempo de incubação (6 h vs. 16 h vs. 24 h) e, (Experimento III) analisar concentrações variáveis (1,0 μg/mL vs. 2,5 μg/mL vs. 10,0 μg/mL) das representações de FSH sobre a MIV de oócitos bovinos. Para tanto, oócitos foram recuperados e submetidos a MIV em condições adequadas. Após a MIV, oócitos foram avaliados quanto à expansão das células do cumulus (CCs), presença do primeiro corpúsculo polar (1CP) e placa metafásica (MII). Todos os dados foram analisados pelo teste exato de Fisher (P 0,05) nas taxas de maturação de oócitos incubados com FSH Pluset® ou Folltropin®, avaliadas pela expansão das CCs (97,6% vs. 94,3%), presença de 1CP (76,6% vs. 69,4%) e MII (70,0% vs. 68,6%). No Experimento II, quanto ao tempo de incubação com FSH foi avaliado, tanto Pluset® quanto Folltropin® mostraram uma menor taxa de expansão de CCs somente nas primeiras 6 h de MIV. Quanto à presença de 1CP, diferenças foram observadas em relação ao Pluset® enquanto o Folltropin® mostrou resultados similares em todos os tempos de incubação. Em relação à MII, nenhuma diferença foi observada entre os tempos de incubação com o FSH Pluset® e Folltropin®. No Experimento III, nenhuma diferença foi observada na expansão das CCs, presença do 1CP e MII para as concentrações avaliadas de FSH Pluset® e Folltropin®. Portanto, FSH Pluset® e Folltropin® tem a mesma eficiência na MIV de oócitos bovinos. Em relação ao tempo de incubação, é recomendado manter o FSH (Pluset® or Folltropin®) ao longo do período da MIV, uma vez que nenhuma diferença foi observada nos resultados da presença de MII...